1. 188P IPH5201 as monotherapy or in combination with durvalumab (D) in advanced solid tumours. (December 2022) Authors: Imbimbo, M.; Hollebecque, A.; Italiano, A.; McKean, M.; Macarulla, T.; Castanon Alvarez, E.; Carneiro, B.A.; Mager, R.; Barnhart, V.; Murtomaki, E.; He, Y.; Cooper, Z.A.; Tu, E.; Linke, A.; Fan, C.; Zhou, D.; Boyer Chammard, A.; Paturel, C.L.; Fraenkel, P.G.; Powderly, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (September 2015) Authors: Van Cutsem, E.; Obermannova, R.; Bodoky, G.; Prausová, J.; García-Carbonero, R.; Ciuleanu, T.; Alfonso, P Garcia; Portnoy, D.; Cohn, A.; Yamazaki, K.; Clingan, P; Yoshino, T.; Polikoff, J.; Lonardi, S.; Macarulla, T.; Yang, L.; Nasroulah, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients. (September 2015) Authors: Sauri, T.; Macarulla, T.; Sanz-Garcia, E.; Moreno, D.; Vilaro, M.; Vivancos, A.; Elez, E.; Argil és, G.; Grasselli, J.; Capdevila, J.; Alsina, M.; Hierro, C.; Matos, I.; Dientsmann, R.; Nuciforo, P.; Tabernero, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S470 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. (September 2015) Authors: Voss, M.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E.L.; Cervantes, A.; Puzanov, I.; Pili, R.; Wang, D.; Jalal, S.; Pant, S.; Patel, M.; Neuwirth, R.; Zohren, F.; Infante, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation. (December 2016) Authors: Kim, R.; Sharma, S.; Meyer, T.; Sarker, D.; Macarulla, T.; Sung, M.; Choo, S.P.; Shi, H.; Schmidt-Kittler, O.; Clifford, C.; Wolf, B.; Llovet, J.M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Management and supportive treatment of frail patients with metastatic pancreatic cancer. Issue 3 (May 2019) Authors: Macarulla, T.; Carrato, A.; Díaz, R.; García, A.; Laquente, B.; Sastre, J.; Álvarez, R.; Muñoz, A.; Hidalgo, M. Journal: Journal of geriatric oncology Issue: Volume 10:Issue 3(2019) Page Start: 398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Management of hyperbilirubinaemia in pancreatic cancer patients. (May 2018) Authors: Álvarez, R.; Carrato, A.; Adeva, J.; Alés, I.; Prados, S.; Valladares, M.; Macarulla, T.; Muñoz, A.; Hidalgo, M. Journal: European journal of cancer Issue: Volume 94(2018) Page Start: 26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PANOVA-3: A Phase 3 Study of Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel (GnP) for Front-Line Treatment of Locally Advanced Pancreatic Adenocarcinoma. (2022) Authors: Picozzi, V.J.; Macarulla, T.; Philip, P.A.; Becerra, C.R.; Dragovich, T. Journal: HPB Issue: Volume 24(2022)Supplement 1 Page Start: S268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Representation of young adult(19–29 y) and elderly(>75 y) patients populations in an early drug development unit. (October 2022) Authors: Vieito Villar, M.; Rojas, K.; Roger, B.; Cristina, V.; Braña, I.; Lostes, J.; Alonso, G.; Galvao, V.; Saavedra, O.; Oberoi, H.; Oiiveira, M.; Gonzalez, M.; Oaknin, A.; Felip, E.; Elez, E.; Saura, C.; Carles, J.; Macarulla, T.; Garralda, E.; Tabernero, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Transition to the new EU CTIS Portal for Regulatory Clinical Trial Submissions: VHIO's Start-Up Unit Analysis. (October 2022) Authors: Matres, A.; Carballo, N.; Bernabé, Y.; Martínez, A.; Silverio, A.; Depares, I.; Cidoncha, I.; Beltran, M.; Braña, I.; Élez, E.; Díez, M.; Muñoz, E.; Saura, C.; Oaknin, A.; Macarulla, T.; Carles, J.; Felip, E.; Tabernero, J.; Garralda, E.; Pérez-Pujol, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗